+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Protein Drugs"

From
From
Eftilagimod alpha (IMP321) Emerging Drug Insight and Market Forecast - 2035 - Product Thumbnail Image

Eftilagimod alpha (IMP321) Emerging Drug Insight and Market Forecast - 2035

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
From
From
From
Plasma Protein Therapeutics Market Report and Forecast 2024-2032 - Product Thumbnail Image

Plasma Protein Therapeutics Market Report and Forecast 2024-2032

  • Report
  • October 2023
  • 140 Pages
  • Global
From
Biopharmaceuticals Market Report and Forecast 2023-2031 - Product Thumbnail Image

Biopharmaceuticals Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 140 Pages
  • Global
From
From
From
From
Loading Indicator

The Protein Drugs market is a subset of the larger Drug Discovery industry. It focuses on the development of drugs that are based on proteins, such as monoclonal antibodies, cytokines, and growth factors. These drugs are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Protein drugs are typically developed through recombinant DNA technology, which involves the manipulation of genetic material to create a desired protein. The Protein Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are engaged in research and development of new protein drugs, as well as the marketing and distribution of existing drugs. Show Less Read more